News

Activation Capital Secures $1.5M to Support Life Sciences Commercialization and Business Formation

The latest funding highlights a series of investments into the Virginia Bio+Tech Park, complementing the City of Richmond’s investment into its Innovation District vision.

RICHMOND, Va., – An omnibus spending bill funding the federal government for the fiscal year 2023 and signed by the president includes $1.5M for Activation Capital, an innovation ecosystem development organization. The funding will support the continued growth and acceleration of life sciences commercialization and business formation in Central Virginia and including those applicable to the emerging advanced pharmaceutical research, development, and manufacturing cluster in the region.

Added to the bill at the request of Virginia Senators Tim Kaine and Mark Warner, the funds will support Activation Capital’s life sciences commercialization, training, and capacity-building efforts.

“This federal funding is a much-needed seed investment into our entrepreneurship growth strategy focused on building a pipeline of entrepreneurs translating high-potential health and life sciences discoveries into high-growth companies,” said Chandra Briggman, President and CEO of Activation Capital, a state-created innovation ecosystem development organization. “Life sciences is a fairly resilient sector – a worthy investment to grow our regional economy, but we need capacity-building support to help actualize its potential. We deeply appreciate Senator Mark Warner and Senator Tim Kaine for their support of our work to strengthen the life sciences ecosystem and the Virginia Bio+Tech Park and create an economic engine for the region.”

“I am proud to support Activation Capital in their mission to build a resilient life sciences research and development workforce in Central Virginia,” said Senator Warner. “This funding, which we secured as part of our bipartisan omnibus spending package, will aid the crucial work of Activation Capital in establishing Central Virginia as a hub for pharmaceutical manufacturing through investment in local entrepreneurship, talent building, and recruitment – spurring economic growth in Petersburg and throughout the region.”

“Central Virginia is already a critical hub for innovative science. Further investment in advanced manufacturing will not only boost our competitiveness and independence from overseas technologies, but also create opportunities for economic growth. I’m glad Activation Capital is receiving these resources from the government funding bill to invest in life sciences research, support skills training, and create jobs by helping startups grow and strengthen the regional economy,” said Senator Kaine.

The 2023 Omnibus spending package to support life sciences commercialization, training, and capacity building follows recent announcements by Activation Capital detailing a transformative $55.9M Build Back Better Regional Challenge award for the region and a $450K GO Virginia Region 4 Grant to design a regional entrepreneurship strategy.

Read more here.

Recent News

02/20/2025

Council on State Biotechnology Associations says NIH funds are a critical component of innovation ecosystem

“Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return

02/11/2025

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions,  announced a strategic partnership with BRAINBox Solutions, a leader in multi-modality diagnostics for traumatic brain injury (TBI). This collaboration seeks to develop the first intranasal therapy for mild traumatic brain injury (mTBI) aka concussion, creating a comprehensive trigger-to-treat

02/11/2025

Children’s National and Compremium partner on pediatric medtech innovation

Children’s National Hospital announced a new collaboration with Swiss medical device company Compremium AG to co-develop and commercialize innovative medical technologies designed specifically for pediatric patients. This first-of-its-kind agreement leverages the expertise of Children’s National in pediatric healthcare innovation and Compremium’s non-invasive platform technology for diagnosing pressure-related conditions, accelerating advancements in pediatric medicine. Diagnosing pressure-related